



PHARMACEUTICAL 2021









PHARMACEUTICAL 2021



Blueprint Medicines Corp Rank 6 of 409



The relative strengths and weaknesses of Blueprint Medicines Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Blueprint Medicines Corp compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 415% points. The greatest weakness of Blueprint Medicines Corp is the variable Other Assets, reducing the Economic Capital Ratio by 32% points.

The company's Economic Capital Ratio, given in the ranking table, is 293%, being 648% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	927,759
Cost of Goods Sold	425
Intangible Assets	0
Liabilities, Current	130,802
Liabilities, Non-Current	117,503
Other Assets	756,505
Other Compr. Net Income	-2,680
Other Expenses	1,058
Other Liabilities	0
Other Net Income	6,233
Property and Equipment	34,129
Research and Development	326,860
Revenues	793,735
Selling, General and Administrative Expense	157,743

Output Variable	Value in 1000 USD
Assets	1,718,393
Liabilities	248,305
Expenses	486,086
Stockholders Equity	1,470,088
Net Income	313,882
Comprehensive Net Income	312,542
Economic Capital Ratio	293%